About Covista 200 97 mg + 103 mg Tablet
Covista 200 is a tablet from Advanced Chemical Industries PLC that combines sacubitril and valsartan. It is prescribed for certain types of heart failure, and the doctor decides the dose and course.
There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. 11 of them have a lower unit price than Covista 200. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.
What is Covista 200 97 mg + 103 mg Tablet?
Covista 200 is a tablet made by Advanced Chemical Industries PLC. It contains two active substances, sacubitril and valsartan, in a strength of 97 mg + 103 mg. This combination belongs to a group of heart failure medicines. Sacubitril works by blocking an enzyme called neprilysin, while valsartan blocks the action of angiotensin II. Together they help the heart and kidneys in heart failure. Covista 200 is used in adults with long-term heart failure and reduced ejection fraction, and in children aged one year and older with symptomatic heart failure. Only a doctor can decide whether this medicine is suitable for a particular patient.
Uses of Covista 200
Covista 200 is used to lower the risk of cardiovascular death and hospitalisation for heart failure in adults with chronic heart failure and reduced ejection fraction. It is also used to treat symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. It is a prescription medicine, and the doctor will confirm whether it is appropriate for the patient's condition.
How to use Covista 200
Covista 200 is taken by mouth as a tablet. The doctor decides the dose and how long it should be taken, based on the patient's condition, kidney and liver function, and other medicines. Do not start, stop or change the dose without the doctor's advice. If a dose is missed, ask the doctor or pharmacist what to do. Swallow the tablet as directed by the doctor.
Side effects of Covista 200
Common side effects of Covista 200 include angioedema (swelling of the face, lips, tongue or throat), low blood pressure, reduced kidney function, high potassium levels, cough and dizziness. Swelling of the face or throat, difficulty breathing, or fainting need urgent medical help. Tell the doctor if dizziness, cough or other effects bother you. The doctor will check kidney function and potassium levels during treatment.
Safety and precautions
Covista 200 must not be used by anyone with a history of angioedema related to ACE inhibitor or ARB therapy, or with hereditary angioedema. It should not be taken with ACE inhibitors or with aliskiren in patients with diabetes. Tell the doctor about all other medicines, especially potassium-sparing diuretics, NSAIDs and lithium. It may lower blood pressure; the doctor will monitor kidney function and potassium. Safety in children under one year is not established. Pregnancy and breastfeeding: ask the doctor before use. Patients with severe liver impairment should not take it.
Frequently asked questions
How should Covista 200 be taken?
Take Covista 200 as your doctor tells you. The doctor decides the dose and how long you need it, based on your health and other medicines. Do not change the dose yourself. If you miss a dose, ask your doctor or pharmacist what to do.
What is Covista 200 used for and what kind of medicine is it?
Covista 200 is a heart failure medicine containing sacubitril and valsartan. It is used in adults with chronic heart failure and reduced ejection fraction to lower the risk of death and hospitalisation, and in children aged one year and older with symptomatic heart failure. Your doctor will decide if it suits you.
What side effects should I watch for and when should I call the doctor?
Watch for swelling of the face, lips, tongue or throat, difficulty breathing, fainting, dizziness or a persistent cough. These need urgent medical help. Tell your doctor about any side effect that bothers you. Your doctor will also check kidney function and potassium levels during treatment.
Can I take Covista 200 with other medicines?
Some medicines should not be taken with Covista 200, including ACE inhibitors and aliskiren in patients with diabetes. Potassium-sparing diuretics, NSAIDs and lithium can also interact. Always tell your doctor or pharmacist about every medicine you take before starting Covista 200.
- Strength
- 97 mg + 103 mg
Price in Bangladesh
৳ 117.6 ৳ 120 2% off unit price
Price updated: 16 Nov 2026
Indications
This is indicated:
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
... Read more
This is indicated:
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.
Pharmacology
This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.
Dosage & Administration
Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
Reduce the starting dose to 24/26 mg twice daily for:
- Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
- Patients with severe renal impairment.
- Patients with moderate hepatic impairment.
Pediatric Heart Failure: Refer to Table 1 for the recommended dose for pediatric patients aged one year and older. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.
Recommended Dose Titration-Pediatric Patients Less than 40 kg:
- Starting: 1.6 mg/kg
- Second: 2.3 mg/kg
- Final: 3.1 mg/kg
Pediatric Patients At least 40 kg, less than 50 kg:
- Starting: 24/26 mg
- Second: 49/51 mg
- Final: 49/51 mg
Pediatric Patients At least 50 kg:
- Starting: 49/51 mg
- Second: 72/78 mg
- Final: 97/103 mg
Interaction
Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.
Contraindications
This combination is contraindicated:
- In patients with hypersensitivity to any component
- In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy
- With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor
- With concomitant use of aliskiren in patients with diabetes
Side Effects
The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.
Pregnancy & Lactation
Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.
Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.
Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.
Precautions & Warnings
This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.
This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.
Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.
Overdose Effects
Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.
Storage Conditions
Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.
Alternative brands of Sacubitril + Valsartan
Other brands with the same generic name, cheapest first.
See all 25 brands
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.